This is the text extract for SA0796 – Ezetimibe, browse documents here.
Ministry of Health Phone 0800 243 666 APPLICANT (stamp or sticker acceptable)
APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 1
Form SA0796
September 2010
PATIENT NHI: ...................................................... REFERRER Reg No: ............................................
Reg No: ................................................................ First Names: ......................................................... First Names: ......................................................... Name: ................................................................... Surname: .............................................................. Surname: .............................................................. Address: ............................................................... DOB: ..................................................................... Address: ............................................................... ............................................................................... Address: ............................................................... ............................................................................... ............................................................................... ............................................................................... ............................................................................... Fax Number: ......................................................... ............................................................................... Fax Number: .........................................................
Ezetimibe
INITIAL APPLICATION Applications only from a relevant specialist. Approvals valid for 2 years. Prerequisites (tick boxes, and write the data requested in the space provided where appropriate)
or
u u
ezetimibe is to be used in combination with simvastatin ezetimibe is to be used without a statin
and
and and
u u
Patient has a calculated absolute risk of cardiovascular disease >20% over 5 years Patient cannot tolerate statin therapy at a dose of ≥ 40 mg per day
and and
u
Patient has venous CABG
LDL cholesterol: ......................................≥ 2 mmol/litre (see note) LDL cholesterol: ......................................≥ 2 mmol/litre (at least 1 week after test 1 – see note) or
and and
u
Patient does not have venous CABG
LDL cholesterol: ......................................≥ 2.5 mmol/litre (see note) LDL cholesterol: ......................................≥ 2.5 mmol/litre (at least 1 week after test 1 – see note) or
and and and
u u
Patient has homozygous familial hypercholesterolemia, or heterozygous familial hypercholesterolemia Patient has been compliant for at least two months with maximum dose statin therapy
LDL cholesterol: ......................................≥ 5 mmol/litre (see note) LDL cholesterol: ......................................≥ 5 mmol/litre (at least 1 week after test 1 – see note) Note: Two lipid tests are required to assess LDL cholesterol levels, the tests must be at least one week apart, and be carried out in a fasted state (other than for patients with IDDM). The results for LDL cholesterol levels in both tests must be above those specified.
Use next page for: Renewal I confirm the above details are correct and that in signing this form I understand I may be audited. Signed: .............................................................................. Date: ...............................................
Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
Ministry of Health Phone 0800 243 666 APPLICANT (stamp or sticker acceptable)
APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY
Page 2
Form SA0796
September 2010
PATIENT NHI: ...................................................... REFERRER Reg No: ............................................
Reg No: ................................................................ First Names: ......................................................... First Names: ......................................................... Name: ................................................................... Surname: .............................................................. Surname: .............................................................. Address: ............................................................... DOB: ..................................................................... Address: ............................................................... ............................................................................... Address: ............................................................... ............................................................................... ............................................................................... ............................................................................... ............................................................................... Fax Number: ......................................................... ............................................................................... Fax Number: .........................................................
Ezetimibe - continued
RENEWAL Current approval Number (if known):............................................................... Applications only from a relevant specialist. Approvals valid for 2 years. Prerequisites (tick boxes where appropriate)
and
u u u
or
The treatment remains appropriate and the patient is benefiting from treatment
ezetimibe is to be used in combination with simvastatin ezetimibe is to be used without a statin
I confirm the above details are correct and that in signing this form I understand I may be audited. Signed: .............................................................................. Date: ...............................................
Post application to Ministry of Health, Private Bag 3015, Wanganui – Fax: 0800 100 131
Metadata
Title
Abstract
Special Authority for Subsidy
Page 1
Note
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.